Zevra Therapeutics, Inc.
Bear Case (25th pct.)
-24.9% vs price
Base Case (Median)
17.7% vs price
Bull Case (75th pct.)
49.1% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $4.51 | -61.0% | High (40%) |
| PE Comparable | $20.70 | 78.9% | Medium (25%) |
| Graham Number | $7.65 | -33.9% | Medium (40%) |
| EV/EBITDA | $17.85 | 54.2% | Medium (20%) |
| EV/FCF | $11.80 | 2.0% | Medium (20%) |
| Earnings Power Value | $15.45 | 33.5% | Medium (50%) |
Based on 6 out of 8 methods, ZVRA appears fairly valued at the current price of $11.57. The base case fair value of $13.62 implies 17.7% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.